Maravai LifeSciences Target of Unusually High Options Trading (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) saw some unusual options trading activity on Wednesday. Investors purchased 1,002 put options on the stock. This represents an increase of approximately 1,791% compared to the typical daily volume of 53 put options.

Insider Activity

In related news, Director Gregory T. Lucier acquired 48,528 shares of the stock in a transaction on Monday, December 8th. The stock was acquired at an average cost of $3.67 per share, for a total transaction of $178,097.76. Following the completion of the acquisition, the director directly owned 155,123 shares of the company’s stock, valued at approximately $569,301.41. This represents a 45.53% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.11% of the stock is owned by corporate insiders.

Institutional Trading of Maravai LifeSciences

A number of institutional investors and hedge funds have recently bought and sold shares of MRVI. Sprott Inc. bought a new position in shares of Maravai LifeSciences in the third quarter worth approximately $29,000. Quantessence Capital LLC purchased a new position in Maravai LifeSciences in the 3rd quarter worth approximately $31,000. Abel Hall LLC bought a new position in Maravai LifeSciences in the 3rd quarter valued at approximately $33,000. CIBC Bancorp USA Inc. purchased a new stake in Maravai LifeSciences during the 3rd quarter valued at $33,000. Finally, Virtu Financial LLC purchased a new stake in Maravai LifeSciences during the 4th quarter valued at $34,000. 50.25% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently issued reports on MRVI shares. Wall Street Zen raised Maravai LifeSciences from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Wells Fargo & Company increased their price objective on Maravai LifeSciences from $4.00 to $4.50 and gave the stock an “overweight” rating in a report on Monday, December 15th. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $4.86.

Maravai LifeSciences Stock Performance

Maravai LifeSciences stock opened at $3.68 on Friday. Maravai LifeSciences has a twelve month low of $1.66 and a twelve month high of $4.11. The company has a quick ratio of 5.69, a current ratio of 6.60 and a debt-to-equity ratio of 0.85. The company has a market capitalization of $941.00 million, a P/E ratio of -4.09 and a beta of 0.38. The stock’s 50 day moving average is $3.46 and its 200 day moving average is $3.23.

Maravai LifeSciences (NASDAQ:MRVI) last released its earnings results on Wednesday, February 25th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.03. Maravai LifeSciences had a negative return on equity of 22.79% and a negative net margin of 70.40%.The business had revenue of $49.87 million for the quarter, compared to the consensus estimate of $49.06 million. On average, equities research analysts predict that Maravai LifeSciences will post -0.24 earnings per share for the current fiscal year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.